- Home
- PTON vs NAMS Comparison
PTON vs NAMS Comparison
Compare PTON & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTON
- NAMS
- Stock Information
- Founded
- PTON 2012
- NAMS 2019
- Country
- PTON United States
- NAMS Netherlands
- Employees
- PTON N/A
- NAMS N/A
- Industry
- PTON Recreational Games/Products/Toys
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- PTON Consumer Discretionary
- NAMS Health Care
- Exchange
- PTON Nasdaq
- NAMS Nasdaq
- Market Cap
- PTON 2.6B
- NAMS 2.5B
- IPO Year
- PTON 2019
- NAMS N/A
- Fundamental
- Price
- PTON $6.56
- NAMS $23.60
- Analyst Decision
- PTON Buy
- NAMS Strong Buy
- Analyst Count
- PTON 18
- NAMS 9
- Target Price
- PTON $7.78
- NAMS $41.11
- AVG Volume (30 Days)
- PTON 10.1M
- NAMS 844.8K
- Earning Date
- PTON 08-21-2025
- NAMS 08-06-2025
- Dividend Yield
- PTON N/A
- NAMS N/A
- EPS Growth
- PTON N/A
- NAMS N/A
- EPS
- PTON N/A
- NAMS N/A
- Revenue
- PTON $2,527,400,000.00
- NAMS $47,140,000.00
- Revenue This Year
- PTON N/A
- NAMS N/A
- Revenue Next Year
- PTON N/A
- NAMS N/A
- P/E Ratio
- PTON N/A
- NAMS N/A
- Revenue Growth
- PTON N/A
- NAMS 586.97
- 52 Week Low
- PTON $2.83
- NAMS $14.06
- 52 Week High
- PTON $10.90
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- PTON 50.16
- NAMS 67.01
- Support Level
- PTON $6.42
- NAMS $22.00
- Resistance Level
- PTON $7.16
- NAMS $24.82
- Average True Range (ATR)
- PTON 0.31
- NAMS 1.21
- MACD
- PTON 0.02
- NAMS 0.25
- Stochastic Oscillator
- PTON 42.31
- NAMS 77.98
About PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of bike and tread and related accessories sales, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue is generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from the International markets.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.